[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"torsades-de-pointes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:torsades-de-pointes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100621718","do-qt-prolonging-drugs-cause-major-adverse-cardiac-events-in-hospitalized-adults-100621718",false,"NCT07374263","Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?","Do 'Known' QT-prolonging Medications Cause Major Adverse Cardiac Events in Hospitalized Adults? The QTP-MACE Study","QTP-MACE","Inclusion Criteria:\n\n* Adult patients 18 years of age or older\n* Admitted to St. Joseph's Healthcare Hamilton or GEMINI hospitals between December 2017 and March 2025\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Outpatient encounters","ALL","18 Years",{"count":20,"type":21},990000,"ESTIMATED","OBSERVATIONAL","There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence. The association between many commonly used medications listed as known QTPmeds and actual major adverse cardiac events (MACE) is weak. Meanwhile, QTPmeds-related warnings are ubiquitous in every healthcare setting, triggering 'hard stop' disruption millions of times per day to front line clinicians. Poor quality medication safety alerts are increasingly recognized as a source of inferior patient care and provider burnout which detracts from healthcare sustainability.\n\nIn this study, anonymized hospital electronic medical record data from more than 990,000 adult patients across Ontario will be used to compare patients who experience MACE with those who do not, measuring their real-time exposure to QT-prolonging drugs. Additionally, machine-learning techniques will also be used to find which patient or treatment factors best predict risk.\n\nThe objectives of this study are to 1) Investigate whether exposure to one or more 'Known' QTPmed is associated with an increased risk of MACE after adjusting for confounders; and 2) Identify predictors and their relative importance for QTPmeds-associated MACE.\n\nIn summary, QT-prolonging medications have the potential to cause very serious adverse events, including death. However, it is not sufficiently clear which patients under which circumstances suffer events, or when is QT prolongation a useful surrogate marker for harm. Meanwhile, ubiquitous medication alerts related to QT-prolonging medications are at best imprecise and at worst, misleading, costly and potentially dangerous. Now that data resources are available with the data elements, structure and sample size required to rigorously assess this association, this study will address this question to improve patient safety, provider satisfaction and the cost-effectiveness of care.",[25,26,27,28,29,30],"Acquired Long QT","Ventricular Arrhythmias","Torsades de Pointes","Syncope","Medication Safety","MACE",[32,33,34,35,36,37],"Medication safety","QT interval prolongation","Long QT syndrome","Ventricular arrhythmia","Torsades de pointes","Major adverse cardiac events","RECRUITING","2026-01-24",{"date":41,"type":42},"2026-01-28","ACTUAL",{"date":44,"type":42},"2025-02-01",{"date":46,"type":21},"2027-12",{"name":48,"class":49},"St. Joseph's Healthcare Hamilton","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":22,"phases":4,"briefSummary":62,"conditions":63,"keywords":76,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",true,{"count":60,"type":21},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[64,65,66,67,68,69,70,71,72,73,74,75],"Arrhythmias, Cardiac","Atrial Fibrillation","Atrial Flutter","Ventricular Tachycardia","Atrial Tachycardia","Arrhythmogenic Right Ventricular Dysplasia","Long QT Syndrome","Brugada Syndrome","Supraventricular Tachycardia","Catecholaminergic Polymorphic Ventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[77,78,79,80,81,82,75],"Catheter Ablation","Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":85,"type":42},"2025-03-30",{"date":87,"type":42},"2021-03-17",{"date":89,"type":21},"2031-12-31",{"name":91,"class":49},"Universitätsklinikum Hamburg-Eppendorf",1]